Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Cardiovascular diseases, resulting from the deposition of clots in blood vessels, are the leading cause of death worldwide. Fibrinolytic enzymatic activity can catalyze blood clot degradation. Findings show that 36 fungal isolates recovered from Caatinga soils have the potential to produce fibrinolytic protease under submerged conditions. About 58 % of the isolates displayed fibrinolytic activity above 100 U/mL, with Mucor subtilissimus UCP 1262 being the most active. The protease was biochemically and biophysically characterized, showing that the enzyme had a high affinity for SAApNA substrate and was significantly inhibited by fluoride methyl phenyl sulfonyl-C7H7FO2S, suggesting that it is a chymotrypsin-like serine protease. The highest enzyme activity was detected at pH 5.0 and 28 °C. This fibrinolytic protease's far-UV circular dichroism (CD) showed that its secondary structure was primarily α-helical. The purified fibrinolytic enzyme may represent a novel therapeutic agent for treating thrombosis. At temperatures above 65 °C, the enzyme lost all its secondary structure. Its melting temperature was 58.1 °C, the denaturation enthalpy 85.1 kcal/mol, and the denaturation entropy 0.26 kcal/K∙mol.

Download full-text PDF

Source
http://dx.doi.org/10.1590/0001-3765202420230616DOI Listing

Publication Analysis

Top Keywords

fibrinolytic protease
8
mucor subtilissimus
8
secondary structure
8
fibrinolytic
6
production biochemical
4
biochemical biophysical
4
biophysical characterization
4
characterization fibrinolytic
4
protease
4
protease mucor
4

Similar Publications

Background: This study aimed to evaluate the predictive value of combining the Padua score with D-dimer levels for identifying lower extremity deep vein thrombosis (DVT) in acute ischemic stroke (AIS) patients undergoing intravenous thrombolysis with alteplase.

Methods: This retrospective study analyzed clinical data from 632 AIS patients who received alteplase treatment at our hospital between September 2019 and October 2023. After applying strict inclusion and exclusion criteria, a total of 172 patients were included in the analysis: 35 patients in the DVT group and 137 patients in the non-DVT group.

View Article and Find Full Text PDF

Aims: The tissue window is increasingly recognized in guiding reperfusion therapy beyond the standard time window in acute ischemic stroke (AIS). This study aims to develop a nomogram incorporating an ischemic core growth rate index to provide individualized prediction of neurological outcomes in AIS patients who received intravenous thrombolysis (IVT).

Methods: A retrospective study was conducted at the First Affiliated Hospital of Soochow University (2016-2023).

View Article and Find Full Text PDF

Hematological malignancies that are frequently complicated with disseminated intravascular coagulation (DIC) include acute leukemia, high-grade malignant lymphoma, and cases undergoing certain immunotherapy or cellular therapy. In typical cases of DIC associated with hematological malignancies, bleeding symptoms are aggravated not only by the activated fibrinolytic system but also by thrombocytopenia induced by the underlying disease or anticancer therapy, and their management is of critical clinical interest. As such, antithrombotic therapy with heparinoids carries significant risk of bleeding complications.

View Article and Find Full Text PDF

Background: The clinical efficacy of intravenous thrombolysis (IVT) for acute ischemic stroke (AIS) associated with intracranial artery dissection (IAD) remains uncertain. This study presents a case of basilar artery dissection (BAD) in a 57-year-old Asian female patient devoid of previous risk factors for stroke who experienced a sudden onset of consciousness disturbance. The patient's clinical condition deteriorated during IVT administration, but subsequent medical intervention and rehabilitative exercises facilitated eventual recovery of daily functioning.

View Article and Find Full Text PDF

Introduction: Acute ischemic stroke (AIS) is the most common type of stroke, with increasing incidence and significant healthcare costs. Tenecteplase (TNK), a modified variant of tissue plasminogen activator (tPA), offers advantages such as a longer half-life and single-bolus administration. This meta-analysis evaluates the safety and efficacy of TNK compared to non-thrombolytic management in AIS to guide clinical decision-making.

View Article and Find Full Text PDF